Kailash Thapaliya

Kailash Thapaliya

Auto-generated profile, based on publicly available information

Kailash Thapaliya

South Australian Health and Medical Research Institute Adelaide SA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TBTanmay Bagade
Tanmay Bagade
KTKailash Thapaliya
Kailash Thapaliya
EBErica Breuer
Erica Breuer
RKRashmi Kamath
Rashmi Kamath
ZLZhuoyang Li
Zhuoyang Li
TMTazeen Majeed
Tazeen Majeed
Infertility affects millions of people globally. Although an estimated 1 in 6 couples in Australia are unable to conceive without medical intervention, little is known about the mental health impacts of infertility. This study investigated how infertility impacts the mental health of women. The study used nationally representative Australian Longitudinal Study on Women's Health (ALSWH) data. We analysed data from survey periods 2–8 conducted every three years between 2000 and 2018 for 6582 women born in 1973–78. We used a Generalised Equation Modelling (GEE) method to investigate the association of primary, secondary and resolved fertility status and psychological distress over time. Multiple measures were used to measure psychological distress: the (1) the mental health index subscale of the 36-item short form survey (SF-36), (2) the Center for Epidemiological Studies Depression Scale (CESD-10), (3) the Goldberg Anxiety and Depression Scale (GADanx) anxiety subscale; and a (4) composite psychological distress variable. About a third (30%) of women reported infertility at any of the survey rounds; a steady increase over 18 years from 1.7% at round 2 to 19.3% at round 8. Half of the women reporting primary or secondary infertility reported psychological distress, with the odds of having psychological distress was higher in women reporting primary (odds ratio (OR) 1.24, 95% confidence interval (CI) 1.06–1.45), secondary (OR 1.27, 95% CI 1.10–1.46) or resolved infertility (OR 1.15, 95% CI 1.05–1.26) compared to women reporting normal fertility status. Women with partners, underweight or higher BMI, smoking, and high-risk alcohol use had higher odds of psychological distress, whereas women in paid work had significantly lower odds of psychological distress (p < 0.001). Diabetes, high blood pressure, asthma, and other chronic physical illness were independently associated with higher odds of psychological distress. Infertility has a significant impact on mental health even after it is resolved. Frequent mental health assessment and a holistic approach to address the lifestyle factors should be undertaken during the treatment of infertility.

1 September 2025 in Medical Journal of Australia
Verified
Journal Article
Open access
KTKailash Thapaliya
Kailash Thapaliya
ASArianne N. Sweeting
Arianne N. Sweeting
KBKirsten I Black
Kirsten I Black
APAmanda Poprzeczny
Amanda Poprzeczny
DMDanielle Mazza
Danielle Mazza
LGLuke E Grzeskowiak
Luke E Grzeskowiak
Objective: To examine longitudinal changes in the initial prescribing of glucagon‐like peptide 1 (GLP‐1) receptor agonists for women of reproductive age in Australia; to determine whether contraception recommendations are being followed; and to estimate the frequency of pregnancy among women using GLP‐1 receptor agonists.Study design: Retrospective open cohort study; analysis of MedicineInsight general practice data.Setting, participants: Women aged 18–49 years who visited participating general practices three or more times during the study period (1 January 2011 – 31 July 2022).Main outcome measures: Age‐standardised incidence of initial GLP‐1 receptor agonist prescribing, by year and type 2 diabetes status; proportion of women using highly effective contraception at the time of GLP‐1 receptor agonist initiation (contraception overlap); age‐standardised incidence of pregnancy within six months of the first prescribing of GLP‐1 receptor agonists.Results: Of 1 635 684 women aged 18–49 years, 18 010 (1.1%) were first prescribed GLP‐1 receptor agonists during 2011–2022, of whom 3739 (20.8%) had type 2 diabetes. The age‐standardised incidence of GLP‐1 receptor agonist prescribing for women with type 2 diabetes increased from 13.0 per 1000 women in 2011 to 88.5 per 1000 women in 2022; for women without type 2 diabetes, it increased from 0 to 14.9 per 1000 women. Of the 6293 women first prescribed GLP‐1 receptor agonists during 2022, 6954 (90.5%) did not have type 2 diabetes. Contraception overlap with first prescribing of GLP‐1 receptor agonists was determined for 3825 women (21.2%). Pregnancies within six months of GLP‐1 receptor agonist prescribing were documented for 232 of 10 781 women for whom at least six months of follow‐up data were available.Conclusions: The prescribing of GLP‐1 receptor agonists for women of reproductive age is increasing in Australia, and most prescriptions are for women not diagnosed with type 2 diabetes. Fewer than one in four women are using contraception at the time of treatment initiation, and a considerable number are pregnant within six months of the initial prescribing of GLP‐1 receptor agonists. Further evidence and guidelines are needed to support the safe and effective use of GLP‐1 receptor agonists by women of reproductive age.

5 August 2021 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
KTKailash Thapaliya
Kailash Thapaliya
MHMelissa L. Harris
Melissa L. Harris
JBJulie E. Byles
Julie E. Byles
Although multiple medications are often utilized to achieve optimal treatment outcomes, polypharmacy (use of five or more medications) among older population is associated with several detrimental effects. Trajectories of polypharmacy among older population over time has not been described. This study estimated polypharmacy prevalence and clusters of individuals with similar patterns of change in polypharmacy among a cohort of older Australian women with and without dementia. Longitudinal prospective cohort data from the oldest birth cohort (1921–1926) of the Australian Longitudinal Study on women's Health (ALSWH) were analysed. Survey data were linked with Pharmaceutical Benefit Schemes (PBS) data to obtain information about the type and number of prescription medications for each year 2003–2015. Group based trajectory modelling was used to identify distinct trajectory groups, based on the presence of polypharmacy for each year of observation. Trajectories were named based on distinctive and meaningful subgroups that followed approximately the same developmental course and probability assignment rule. Generalized estimating equation was used to identify factors associated with polypharmacy. A total of 10,372 women were eligible for the inclusion in the study. Prevalence of polypharmacy increased over time and reached as high as 71.19% and 71.29% in 2014 for women with and without dementia, respectively. Four distinct polypharmacy trajectories were identified: ‘Consistent Polypharmacy’ (55.88%);‘Low Polypharmacy’ (24.52%); ‘Rapid Increasing Polypharmacy’ (12.50%); and ‘Moderate Polypharmacy’ (7.12%). Dementia, Residential Aged Care (RAC), frailty and comorbid condition were the key drivers of polypharmacy in this cohort. The prevalence of polypharmacy among older women increased over time, with most women have a pattern of consistent polypharmacy or rapidly increasing polypharmacy. Appropriate, sustainable, and effective strategies for reducing medication use should be implemented for women as they age, and particularly for those with dementia and those in residential care.

26 December 2022 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
KTKailash Thapaliya
Kailash Thapaliya
VCVictoria Cornell
Victoria Cornell
CLCatherine Lang
Catherine Lang
GCGillian E. Caughey
Gillian E. Caughey
ABAnna Barker
Anna Barker
MIMaria C. Inacio
Maria C. Inacio

28 January 2015 in Journal of Chitwan Medical College
Verified
Journal Article
Closed access
PDF file
KTK Thapaliya
K Thapaliya
ASA Shrestha
A Shrestha
APA Prajapti
A Prajapti
RSR Subedi
R Subedi
SGS Giri
S Giri
Adverse Drug Reactions (ADRs) are a global problem adding to the economic burden of the society. Anti-cancer drugs are prone to cause ADRs and there is lack of pharmacovigillance data on such type drugs. Therefore, the present study was undertaken to monitor suspected ADRs in the cancer chemotherapy with its management in B.P. Koirala Memorial Cancer Hospital (BPKMCH). The study was done in the inpatient department of BPKMCH from May, 2014 to July, 2014, among the patients receiving chemotherapy. It was a hospital based prospective observational study. Most commonly occurring cancer were lung (16%), ovary (15%), cervix (11%), breast, blood, and throat (9%). Most frequently used drugs for cancer chemotherapy were paclitaxel (25%), cyclophosphamide (18%), vincristine (9%), cisplatin (11%) and adriamycin (6%). Most common ADRs experienced were nausea & vomiting (85.45%), loss of appetite (72.72%), mucositis (65.45%), pain (63.63%), loss of breath (40%), constipation (52.72%) and polyneuropathy (58.18%). DOI:http://dx.doi.org/10.3126/jcmc.v4i4.11967

15 October 2025 in Medical Journal of Australia
Verified
Journal Article
Closed access
DMDanielle Mazza
Danielle Mazza
KTKailash Thapaliya
Kailash Thapaliya
SCSharinne B Crawford
Sharinne B Crawford
AHAlissia Hui
Alissia Hui
MMMaryam Moradi
Maryam Moradi
LGLuke E Grzeskowiak
Luke E Grzeskowiak
Objective: To examine the presentation, investigation, and clinical management of women diagnosed with endometriosis in Australian general practices during 2011–2021. Study design: Open cohort study; analysis of MedicineInsight data. Setting, participants: Women aged 14–49 years who were active patients at Australian general practices participating in MedicineInsight and were diagnosed with endometriosis at these practices, 1 January 2011 – 31 December 2021. Main outcome measures: The number of women with first documented diagnoses of endometriosis in general practices and the annual age‐standardised prevalence; documented symptoms prior to documented endometriosis diagnosis; time from initial symptoms to diagnosis; general practitioner requests for diagnostic investigations and prescribing of medications. Results: First diagnoses of endometriosis at their regular general practices were recorded for 19 786 women during 2011–2021; the annual age‐standardised prevalence increased from 1.78 per 100 women in 2011 to 2.86 per 100 women in 2021. At least one symptom was documented prior to diagnosis for 13 202 women (66.7%), including 8073 (40.8%) with pelvic pain and 4371 (22.1%) with dysmenorrhea. The median time from first symptom documentation to first documented endometriosis diagnosis was 2.5 years (interquartile range, 0.9–5.6 years). The proportion of women for whom general practitioners requested pelvic ultrasound prior to diagnosis increased from 202 of 1068 of those diagnosed in 2011 (18.9%) to 1099 of 2259 women diagnosed in 2021 (48.6%). The proportions of women who received general practitioner prescriptions were larger during the five years after than the five years preceding endometriosis diagnoses for levonorgestrel intrauterine devices (odds ratio [OR], 1.50; 95% confidence interval [CI], 1.36–1.65) and non‐contraceptive progestogens (OR, 1.65; 95% CI, 1.51–1.81), and smaller for oral contraceptive pills (OR, 0.47; 95% CI, 0.45–0.50). The proportions of women prescribed opioids (OR, 1.35; 95% CI, 1.29–1.42), tricyclic antidepressants (OR, 1.93; 95% CI, 1.77–2.11), and gabapentinoids (OR, 2.60; 95% CI, 2.30–2.91) were also larger after endometriosis diagnoses; the proportion for each medication type was highest one year after diagnosis, but then declined. Conclusion: Our findings provide unique insights into the presentation and management of endometriosis in Australian general practice and could inform interventions for improving the clinical management of this often debilitating condition.